Clinical trials: Ovarian, Fallopian, and Primary Peritoneal Cancer
Ovarian Cancer, Peritoneal Primary Cancer
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
RATIONALE: Chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ovarian Cancer, Peritoneal Primary Cancer, Fallopian Tube Cancer
- Trial name
- NCT00293293
- Testing
- healing touch, massage therapy, hypnosis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed…
- Trial name
- NCT03079687
- Testing
- Olaparib tablets
- Where
- 13 sites in United States
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
RATIONALE: Biological therapies, such as denileukin difitox, may stimulate the immune system in different ways and may prevent tumor cells from growing.
- Conditions
- Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma
- Trial name
- NCT00357448
- Testing
- denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Washington
Ovarian Carcinoma
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
- Trial name
- NCT06028932
- Testing
- Sacituzumab govitecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Ovarian Endometrioid Tumor, Fallopian Tube Cancer
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
This study is being done to look at the combination of the drugs atezolizumab and bevacizumab as a maintenance treatment (treatment given after the main treatment to keep the cancer from coming back or worsening) following…
- Conditions
- Ovarian Endometrioid Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer, TP53 Mutation
- Trial name
- NCT04510584
- Testing
- Atezolizumab, Bevacizumab
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Ovarian Cancer
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis…
- Trial name
- TEACO (NCT00296816)
- Testing
- Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Sanofi
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00373217
- Testing
- MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine, tetanus toxoid helper peptide, carboplatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Craig L Slingluff, Jr
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma
Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)
This study aims to assess the safety and tolerability of PHI-101 in patients with platinum-resistance/refractory ovarian, fallopian tubal, and primary peritoneal cancer.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- CREATIVE (NCT04678102)
- Testing
- PHI-101 administration
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Seoul National University Hospital
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib (Rucaparib…
- Trial name
- MITO25 (NCT03462212)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 7 sites in Italy
- Volunteers
- 290 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian…
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor
- Trial name
- NCT01167712
- Testing
- Bevacizumab, Carboplatin, Computed Tomography
- Where
- 564 sites in United States, Canada and 1 more
- Volunteers
- 692 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00616941
- Testing
- NY-ESO-1 OLP4, NY-ESO-1 OLP4 + Montanide, NY-ESO-1 OLP4 + Montanide + Poly-ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ludwig Institute for Cancer Research
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00112957
- Testing
- rV-NY-ESO-1 vaccine, rF-NY-ESO-1 vaccine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ludwig Institute for Cancer Research
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH
Ovarian Carcinoma, Fallopian Tube Cancer
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01312376
- Testing
- OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ovarian Cancer
Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission
The purpose of this study is to evaluate the efficacy and safety of catumaxomab as consolidation treatment in patients with epithelial ovarian cancer in second or third complete remission.
- Trial name
- NCT01246440
- Testing
- Catumaxomab
- Where
- 17 sites in Spain
- Volunteers
- 39 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian…
- Conditions
- FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer, FIGO Stage III Primary Peritoneal Cancer
- Trial name
- NCT03054909
- Testing
- ALT-803 Subcutaneous, ALT-803 Intraperitoneal
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Fallopian Tube Cancers
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- BACON (NCT07489300)
- Testing
- Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
This pilot clinical trial studies the effect of pembrolizumab and lenvatinib in treating patients with high-grade serous ovarian cancers.
- Conditions
- High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT05114421
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
This phase II trial studies how well dasatinib works in treating patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02059265
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 227 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
- Trial name
- NCT02502266
- Testing
- Cediranib, Cediranib Maleate, Computed Tomography
- Where
- 398 sites in United States, Canada and 3 more
- Volunteers
- 582 people
- Sponsor
- National Cancer Institute (NCI)